Krishna Kumar Veeravalli, PhD
Henderson Professor in Neuroscience Research
Associate Professor
Cancer Biology and Pharmacology
Contact
Address:
1 Illini Drive, Peoria, IL, 61605
Office Phone:
Fax:
Email:
About
Expertise
- Stroke and spinal cord injury research
- Teaching (Pharmacology)
- Industry (Preclinical toxicology, Safety Pharmacology, GLP, Generics, Impurity qualifications)
Positions
- 2003-2007: Research Scientist, Ranbaxy Laboratories Limited, India
- 2007-2010: Postdoctoral Research Associate, UICOMP
- 2010-2014: Research Assistant Professor of Cancer Biology and Pharmacology, UICOMP
- 2014-2020: Assistant Professor (tenure-track) of Cancer Biology and Pharmacology, UICOMP
- 2020-present: Associate Professor (tenured) of Cancer Biology and Pharmacology, UICOMP
Appointments
- 2005-2007: Study Director of Toxicology & Safety Pharmacology Studies, Ranbaxy Laboratories Limited
- 2014-2018: Co-Director of Medical Pharmacology Course, UICOMP
- 2014-2020: Assistant Professor of Neurosurgery, UICOMP
- 2015-2020: Assistant Professor of Neurology, UICOMP
- 2018-present: Affiliate, Department of Health Sciences Education, UICOM-Rockford
- 2019-present: Affiliate, Department of Biomedical Sciences, UICOM-Rockford
- 2019-present: Director of Institutional Animal Care and Use Program, UICOMP
- 2020-present: Associate Professor of Neurosurgery, UICOMP
- 2020-present: Associate Professor of Neurology, UICOMP
- 2021-present: Associate Professor of Pediatrics, UICOMP
- 2022-present: John and Beverly Henderson Endowed Professor in Neuroscience Research, UICOMP
Selected Grants
American Heart Association (23TPA1061995), “Development of scFv antibodies against MMP-12 for stroke treatment” July 2023–June 2026 | Total Costs $300,000, PI
William E. McElroy Charitable Foundation, “Novel treatment for reducing the detrimental effects of delayed tPA treatment for ischemic stroke” July 2023-June 2025 | Total Costs $50,000, PI
William E. McElroy Charitable Foundation, “Targeting toll-like receptor signaling to mitigate brain injury and improve neurological recovery after ischemic stroke” July 2020–June 2022 | Total Costs $36,450, PI
OSF Illinois Neurological Institute, “Targeting MyD88 to attenuate post-ischemic inflammation and improve post-stroke outcome” Feb 2019–Feb 2020 | Total Costs $17,500, PI
NIH/NINDS (R01 NS102573), “MMP-12 and post-stroke brain damage” Sept 2018–June 2024 | Total Costs $1,755,322, PI
William E. McElroy Charitable Foundation, “Stem cell-derived exosomes: effect of treatment on post-stroke neurological function” July 2018–June 2020 | Total Costs $44,701, PI
William E. McElroy Charitable Foundation, "Stem cell treatment after ischemic stroke: Gender differences in stroke severity and treatment outcome” July 2015–June 2017 | Total Costs $31,680, PI
OSF HealthCare Foundation and Illinois Neurological Institute, “Combination therapy for the treatment of ischemic stroke in a rat model of focal cerebral ischemia” Aug 2014–Aug 2018 | Total Costs $330,000, PI
William E. McElroy Charitable Foundation, “Growth inhibition of glioma cells including glioma stem cells and non-stem glioma cells by cord blood stem cells” July 2011–June 2013 | Total Costs $55,000, PI
Selected Publications
Challa SR, Nalamolu KR, Fornal CA, Mohandass A, Mussman JP, Schaibley C, Kashyap A, Sama V, Wang BC, Klopfenstein JD, Pinson DM, Kunamneni A, Veeravalli KK. The interplay between MMP-12 and t-PA in the brain after ischemic stroke. Neurochemistry International 2022; 161: 105436.
Challa SR, Nalamolu KR, Fornal CA, Wang BC, Martin RC, Olson EA, Ujjainwala AL, Pinson DM, Klopfenstein JD, Veeravalli KK. Therapeutic efficacy of MMP-12 suppression on neurological recovery after ischemic stroke: optimal treatment timing and duration. Frontiers in Neuroscience 2022; 16: 1012812.
Nalamolu KR, Chelluboina B, Fornal CA, Challa SR, Pinson DM, Wang DZ, Klopfenstein JD, Veeravalli KK. Stem cell treatment improves post-stroke neurological outcomes: A comparative study in male and female rats. Stroke and Vascular Neurology 2021; 6: 519-527.
Nalamolu KR, Challa SR, Fornal CA, Grudzien NA, Jorgenson LC, Choudry MM, Smith NJ, Palmer CJ, Pinson DM, Klopfenstein JD, Veeravalli KK. Attenuation of the induction of TLRs 2 and 4 mitigates inflammation and promotes neurological recovery after focal cerebral ischemia. Translational Stroke Research 2021; 12: 923-936.
Nalamolu KR, Venkatesh I, Mohandass A, Klopfenstein JD, Pinson DM, Wang DZ, Kunamneni A, Veeravalli KK. Exosomes secreted by the cocultures of normal and oxygen-glucose deprived stem cells improve post-stroke outcome. NeuroMolecular Medicine 2019; 21: 529-539.
Nalamolu KR, Venkatesh I, Mohandass A, Klopfenstein JD, Pinson DM, Wang DZ, Veeravalli KK. Exosomes treatment mitigates ischemic brain damage but does not improve post-stroke neurological outcome. Cell Physiol and Biochem 2019; 52: 1280-1291.
Nalamolu KR, Smith NJ, Chelluboina B, Klopfenstein JD, Pinson DM, Wang DZ, Vemuganti R, Veeravalli KK. Prevention of the severity of post-ischemic inflammation and brain damage by simultaneous knockdown of toll-like receptors 2 and 4. Neuroscience 2018; 373: 82-91.
Chelluboina B, Klopfenstein JD, Pinson DM, Wang DZ, Vemuganti R, Veeravalli KK. Matrix metalloproteinase-12 induces blood-brain barrier damage after focal cerebral ischemia. Stroke 2015; 46: 3523-3531.
Chelluboina B, Warhekar A, Dillard M, Klopfenstein JD, Pinson DM, Wang DZ, Veeravalli KK. Post-transcriptional inactivation of matrix metalloproteinase-12 after focal cerebral ischemia attenuates brain damage. Scientific Reports 2015; 5: 9504.
Chelluboina B, Klopfenstein JD, Gujrati M, Rao JS, Veeravalli KK. Temporal regulation of apoptotic and anti-apoptotic molecules after middle cerebral artery occlusion followed by reperfusion. Molecular Neurobiology 2014; 49: 50-65.
Veeravalli KK, Dasari VR, Fassett D, Dinh DH, Rao JS. Human umbilical cord blood derived mesenchymal stem cells upregulate myelin basic protein in shiverer mice. Stem Cells and Development 2011; 20: 881-891.
Veeravalli KK, Dasari VR, Tsung AJ, Dinh DH, Gujrati M, Fassett D, Rao JS. Human umbilical cord blood stem cells upregulate matrix metalloproteinase-2 in rats after spinal cord injury. Neurobiology of Disease 2009; 36: 200-212.
Veeravalli KK, Dasari VR, Tsung AJ, Dinh DH, Gujrati M, Fassett D, Rao JS. Stem cells downregulate the elevated levels of tissue plasminogen activator in rats after spinal cord injury. Neurochemical Research 2009; 34: 1183-1194.
Veeravalli KK, Akula A. Involvement of nitric oxide and prostaglandin pathways in the cardioprotective actions of bradykinin in rats with experimental myocardial infarction. Pharmacol Res 2004; 49: 23-29.
Veeravalli KK, Akula A, Routhu KV, Kota MK. Infarct size limiting effect of apstatin alone and in combination with enalapril, lisinopril and ramipril in rats with experimental myocardial infarction. Pharmacol Res 2003; 48: 557-563.
Notable Honors
2023, Distinguished Research Mentor Award, UICOMP
2023, Transformational Project Award, American Heart Association
2023, Outstanding Service Award, UICOMP
2022, Endowed Professorship in Neuroscience Research, John and Beverly Henderson
2020, Teaching Excellence Award, UICOMP Students
2019, Golden Apple Award, UICOMP Students
2019, Outstanding Research Award, UICOMP
2018, Teaching Recognition Program Award, University of Illinois Chicago
2018, Outstanding Teaching Award, UICOMP
2017, Outstanding Research Award, UICOMP
Education
Education/Training
1994-1998: B.Pharm., College of Pharmaceutical Sciences, Andhra University
1998-2000: M.Pharm., College of Pharmaceutical Sciences, Andhra University
2000-2005: Ph.D., College of Pharmaceutical Sciences, Andhra University
2007-2010: Postdoc, UICOMP